BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22954485)

  • 1. Thromboembolic events and anti-tumor necrosis factor therapies.
    Masson PL
    Int Immunopharmacol; 2012 Dec; 14(4):444-5. PubMed ID: 22954485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha-induced systemic lupus syndrome.
    Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
    Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
    [No Abstract]   [Full Text] [Related]  

  • 6. Skin lesions and treatment with tumor necrosis factor alpha antagonists.
    Hernández MV; Meineri M; Sanmartí R
    Reumatol Clin; 2013; 9(1):53-61. PubMed ID: 22766431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 8. Schnitzler's syndrome--exacerbation after anti-TNF treatment.
    Thonhofer R; Uitz E; Graninger W
    Rheumatology (Oxford); 2007 Jun; 46(6):1041-2. PubMed ID: 17449490
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S
    J Rheumatol Suppl; 2005 Mar; 74():35-9. PubMed ID: 15742463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TNF-alpha inhibitors and demyelinating disease].
    Böttiger Y
    Lakartidningen; 2007 Nov 7-13; 104(45):3384. PubMed ID: 18062640
    [No Abstract]   [Full Text] [Related]  

  • 12. [Lupus like syndrome induced by treatment with anti TNFalpha (infliximab): report of three cases].
    Benucci M; Nenci G; Cappelletti C; Manfredi M
    Recenti Prog Med; 2008; 99(7-8):363-6. PubMed ID: 18751615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-α antagonists: Side effects and their management.
    Dogra S; Khullar G
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S35-46. PubMed ID: 23974693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 16. Tuberculosis infections and tumor necrosis factor alpha antagonists.
    Gan J; Manadan AM; Sequiera W; Block JA
    Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
    Ubriani R; Van Voorhees AS
    Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuberculosis and anti-TNF-alpha treatment.
    Ormerod LP
    Thorax; 2004 Nov; 59(11):921. PubMed ID: 15516463
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
    Bendtzen K
    Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumour necrosis factor inhibitors--what we need to know.
    Hasan U
    N Z Med J; 2006 Dec; 119(1246):U2336. PubMed ID: 17151710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.